Stock Scorer

Caribou Biosciences, Inc. (CRBU)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 9M 18M 27M Q3 '21: 4M Q4 '21: 2.6M Q1 '22: 2.7M Q2 '22: 4.2M Q3 '22: 3.3M Q4 '22: 3.7M Q1 '23: 3.5M Q2 '23: 3.8M Q3 '23: 23.7M Q4 '23: 3.6M Q1 '24: 2.4M Q2 '24: 3.5M Q3 '24: 2M Q4 '24: 2.1M Q1 '25: 2.4M Q2 '25: 2.7M Q3 '25: 2.2M Q4 '25: 3.9M Q1 '26: 2.4M Q2 '26: 1.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -18.6M Q4 '21: -20.4M Q1 '22: -20.9M Q2 '22: -28.4M Q3 '22: -26.5M Q4 '22: -30.6M Q1 '23: -31.1M Q2 '23: -32.9M Q3 '23: -14.6M Q4 '23: -37.4M Q1 '24: -46M Q2 '24: -43.5M Q3 '24: -38.2M Q4 '24: -38.9M Q1 '25: -42.9M Q2 '25: -47.6M Q3 '25: -29.4M Q4 '25: -28.5M Q1 '26: -26.3M Q2 '26: -25.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -21M Q4 '21: -18.5M Q1 '22: -19.1M Q2 '22: -26.7M Q3 '22: -26.6M Q4 '22: -27M Q1 '23: -28M Q2 '23: -29.5M Q3 '23: -10M Q4 '23: -34.5M Q1 '24: -41.2M Q2 '24: -37.7M Q3 '24: -34.7M Q4 '24: -35.5M Q1 '25: -40M Q2 '25: -54.1M Q3 '25: -27.5M Q4 '25: -26.5M Q1 '26: -25.1M Q2 '26: -24.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -15M Q4 '21: -21.4M Q1 '22: -21.7M Q2 '22: -21.9M Q3 '22: -22.4M Q4 '22: -25M Q1 '23: -27.9M Q2 '23: -15.2M Q3 '23: -28.8M Q4 '23: -21.4M Q1 '24: -37.2M Q2 '24: -32.9M Q3 '24: -32.7M Q4 '24: -35.5M Q1 '25: -36.7M Q2 '25: -28.3M Q3 '25: -25.2M Q4 '25: -20.8M Q1 '26: -27M Q2 '26: -22.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q2 '21: -17M Q3 '21: -15.9M Q4 '21: -22.1M Q1 '22: -22.4M Q2 '22: -24.5M Q3 '22: -23.7M Q4 '22: -26.8M Q1 '23: -30M Q2 '23: -17.7M Q3 '23: -33.5M Q4 '23: -23.7M Q1 '24: -38.7M Q2 '24: -35.1M Q3 '24: -33.3M Q4 '24: -36M Q1 '25: -37.8M Q2 '25: -28.7M Q3 '25: -25.3M Q1 '26: -27.1M Q2 '26: -22.8M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q2 '21: 10.3M Q3 '21: 45.9M Q1 '22: 60.5M Q2 '22: 60.8M Q3 '22: 60.9M Q1 '23: 61.2M Q2 '23: 61.4M Q3 '23: 83.8M Q1 '24: 89.3M Q2 '24: 90.3M Q3 '24: 90.5M Q1 '25: 92.7M Q2 '25: 93M Q3 '25: 93.3M Q1 '26: 95.9M Q2 '26: 101M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q3 '21: -4.92 Q4 '21: -3.55 Q1 '22: -2.48 Q2 '22: -1.53 Q3 '22: -1.51 Q4 '22: -1.65 Q1 '23: -1.79 Q2 '23: -1.83 Q3 '23: -1.51 Q4 '23: -1.46 Q1 '24: -1.46 Q2 '24: -1.40 Q3 '24: -1.66 Q4 '24: -1.65 Q1 '25: -1.62 Q2 '25: -1.78 Q3 '25: -1.70 Q4 '25: -1.59 Q1 '26: -1.42 Q2 '26: -1.08 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for CRBU: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.